Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 43.43 Million USD | 125.19% |
| 2022 | 19.28 Million USD | -15.29% |
| 2021 | 22.76 Million USD | 130.6% |
| 2020 | 9.87 Million USD | -44.09% |
| 2019 | 17.66 Million USD | 425.41% |
| 2018 | -5.42 Million USD | -117.33% |
| 2017 | 31.31 Million USD | 25.32% |
| 2016 | 24.98 Million USD | 34326.03% |
| 2015 | -73 Thousand USD | -100.59% |
| 2014 | 12.27 Million USD | 171.03% |
| 2013 | -17.27 Million USD | -397.32% |
| 2012 | -3.47 Million USD | -122.8% |
| 2011 | 15.23 Million USD | 55.43% |
| 2010 | 9.8 Million USD | 23.38% |
| 2009 | 7.94 Million USD | 6.13% |
| 2008 | 7.48 Million USD | 195.22% |
| 2007 | -7.86 Million USD | -457.64% |
| 2006 | 2.19 Million USD | -65.35% |
| 2005 | 6.34 Million USD | 109.51% |
| 2004 | 3.02 Million USD | 2623.33% |
| 2003 | -120 Thousand USD | 93.84% |
| 2002 | -1.94 Million USD | 86.82% |
| 2001 | -14.77 Million USD | -445.94% |
| 2000 | 4.27 Million USD | 88.93% |
| 1999 | 2.26 Million USD | 454.39% |
| 1998 | -638 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 46.59 Million USD | 7.29% |
| 2024 Q2 | 52.69 Million USD | 13.08% |
| 2023 Q1 | 25.17 Million USD | 30.51% |
| 2023 Q3 | 31.34 Million USD | 6.85% |
| 2023 Q2 | 29.33 Million USD | 16.53% |
| 2023 Q4 | 43.43 Million USD | 38.58% |
| 2023 FY | 43.43 Million USD | 125.19% |
| 2022 Q4 | 19.28 Million USD | -8.8% |
| 2022 Q3 | 21.15 Million USD | -20.25% |
| 2022 Q1 | 26.65 Million USD | 17.05% |
| 2022 FY | 19.28 Million USD | -15.29% |
| 2022 Q2 | 26.52 Million USD | -0.49% |
| 2021 FY | 22.76 Million USD | 130.6% |
| 2021 Q1 | 17.32 Million USD | 75.48% |
| 2021 Q3 | 22.17 Million USD | 0.59% |
| 2021 Q2 | 22.04 Million USD | 27.24% |
| 2021 Q4 | 22.76 Million USD | 2.67% |
| 2020 Q4 | 9.87 Million USD | -32.0% |
| 2020 FY | 9.87 Million USD | -44.09% |
| 2020 Q3 | 14.52 Million USD | -2.47% |
| 2020 Q2 | 14.88 Million USD | -9.51% |
| 2020 Q1 | 16.45 Million USD | -6.84% |
| 2019 Q2 | 14.45 Million USD | 113.19% |
| 2019 Q1 | 6.77 Million USD | 224.89% |
| 2019 FY | 17.66 Million USD | 425.41% |
| 2019 Q4 | 17.66 Million USD | 6.51% |
| 2019 Q3 | 16.58 Million USD | 14.75% |
| 2018 Q4 | -5.42 Million USD | -117.16% |
| 2018 FY | -5.42 Million USD | -117.33% |
| 2018 Q1 | 31.53 Million USD | 0.7% |
| 2018 Q2 | 31.19 Million USD | -1.07% |
| 2018 Q3 | 31.62 Million USD | 1.38% |
| 2017 Q2 | 32 Million USD | 1.83% |
| 2017 Q1 | 31.43 Million USD | 25.8% |
| 2017 FY | 31.31 Million USD | 25.32% |
| 2017 Q4 | 31.31 Million USD | 20.67% |
| 2017 Q3 | 25.94 Million USD | -18.92% |
| 2016 Q2 | 19.21 Million USD | 86.81% |
| 2016 Q1 | 10.28 Million USD | 14190.41% |
| 2016 Q3 | 19.8 Million USD | 3.05% |
| 2016 FY | 24.98 Million USD | 34326.03% |
| 2016 Q4 | 24.98 Million USD | 26.17% |
| 2015 Q1 | 26.99 Million USD | 120.0% |
| 2015 Q3 | 16.23 Million USD | 283.22% |
| 2015 Q2 | 4.23 Million USD | -84.31% |
| 2015 Q4 | -73 Thousand USD | -100.45% |
| 2015 FY | -73 Thousand USD | -100.59% |
| 2014 Q4 | 12.27 Million USD | -20.75% |
| 2014 Q3 | 15.48 Million USD | 301.61% |
| 2014 Q2 | -7.68 Million USD | 30.54% |
| 2014 Q1 | -11.05 Million USD | 36.0% |
| 2014 FY | 12.27 Million USD | 171.03% |
| 2013 FY | -17.27 Million USD | -397.32% |
| 2013 Q3 | -1.25 Million USD | -530.14% |
| 2013 Q1 | 3.04 Million USD | 187.62% |
| 2013 Q2 | 292 Thousand USD | -90.41% |
| 2013 Q4 | -17.27 Million USD | -1275.56% |
| 2012 Q4 | -3.47 Million USD | -115.76% |
| 2012 Q2 | 19.86 Million USD | 21.3% |
| 2012 FY | -3.47 Million USD | -122.8% |
| 2012 Q1 | 16.37 Million USD | 7.48% |
| 2012 Q3 | 22.04 Million USD | 10.99% |
| 2011 Q1 | 10.05 Million USD | 2.55% |
| 2011 FY | 15.23 Million USD | 55.43% |
| 2011 Q4 | 15.23 Million USD | 43.58% |
| 2011 Q3 | 10.61 Million USD | 97.4% |
| 2011 Q2 | 5.37 Million USD | -46.52% |
| 2010 Q1 | 8.55 Million USD | 7.68% |
| 2010 Q2 | 7.84 Million USD | -8.28% |
| 2010 Q3 | 10.04 Million USD | 28.04% |
| 2010 Q4 | 9.8 Million USD | -2.44% |
| 2010 FY | 9.8 Million USD | 23.38% |
| 2009 Q4 | 7.94 Million USD | 7.47% |
| 2009 FY | 7.94 Million USD | 6.13% |
| 2009 Q2 | 8.79 Million USD | 8.19% |
| 2009 Q3 | 7.39 Million USD | -15.96% |
| 2009 Q1 | 8.13 Million USD | 8.62% |
| 2008 Q2 | 2.86 Million USD | 211.09% |
| 2008 FY | 7.48 Million USD | 195.22% |
| 2008 Q4 | 7.48 Million USD | 44.25% |
| 2008 Q3 | 5.18 Million USD | 81.18% |
| 2008 Q1 | -2.57 Million USD | 67.21% |
| 2007 FY | -7.86 Million USD | -457.64% |
| 2007 Q1 | 3.62 Million USD | 64.88% |
| 2007 Q2 | -20.27 Million USD | -659.44% |
| 2007 Q3 | -11.63 Million USD | 42.63% |
| 2007 Q4 | -7.86 Million USD | 32.42% |
| 2006 Q2 | -1.94 Million USD | -141.31% |
| 2006 Q3 | 144 Thousand USD | 107.4% |
| 2006 Q4 | 2.19 Million USD | 1426.39% |
| 2006 FY | 2.19 Million USD | -65.35% |
| 2006 Q1 | 4.7 Million USD | -25.79% |
| 2005 FY | 6.34 Million USD | 109.51% |
| 2005 Q1 | 3.96 Million USD | 30.94% |
| 2005 Q4 | 6.34 Million USD | 15.89% |
| 2005 Q2 | 4.78 Million USD | 20.68% |
| 2005 Q3 | 5.47 Million USD | 14.4% |
| 2004 FY | 3.02 Million USD | 2623.33% |
| 2004 Q4 | 3.02 Million USD | 72.63% |
| 2004 Q3 | 1.75 Million USD | 2148.72% |
| 2004 Q1 | 67 Thousand USD | 155.83% |
| 2004 Q2 | 78 Thousand USD | 16.42% |
| 2003 Q4 | -120 Thousand USD | 78.46% |
| 2003 Q2 | -483 Thousand USD | 77.31% |
| 2003 Q3 | -557 Thousand USD | -15.32% |
| 2003 Q1 | -2.12 Million USD | -9.29% |
| 2003 FY | -120 Thousand USD | 93.84% |
| 2002 Q1 | -11.07 Million USD | 25.04% |
| 2002 Q2 | -7.21 Million USD | 34.88% |
| 2002 Q3 | -3.82 Million USD | 46.99% |
| 2002 Q4 | -1.94 Million USD | 49.06% |
| 2002 FY | -1.94 Million USD | 86.82% |
| 2001 Q4 | -14.77 Million USD | -774.41% |
| 2001 FY | -14.77 Million USD | -445.94% |
| 2001 Q1 | -14.12 Billion USD | 0.0% |
| 2001 Q3 | -1.69 Million USD | 62.19% |
| 2001 Q2 | -4.47 Million USD | 99.97% |
| 2000 FY | 4.27 Million USD | 88.93% |
| 1999 FY | 2.26 Million USD | 454.39% |
| 1998 FY | -638 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 3315672.519% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -668.965% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -1.498% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 17500.048% |
| Rebus Holdings, Inc. | 305 Thousand USD | -14140.656% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 788.934% |
| Qrons Inc. | 351.42 Thousand USD | -12259.324% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -6878.874% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 212928.303% |
| Skye Bioscience, Inc. | -5.72 Million USD | 859.151% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -175.544% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -954.729% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -10708.538% |
| SQZ Biotechnologies Company | -36.23 Million USD | 219.858% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -1837.087% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -4584.497% |
| Mesoblast Limited | 55.85 Million USD | 22.242% |
| Marizyme, Inc. | 18.56 Million USD | -133.906% |
| Genus plc | 190.6 Million USD | 77.212% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -1842.633% |
| Pharming Group N.V. | 109.8 Million USD | 60.444% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -4949.05% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -3478.09% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -6287.353% |
| ContraFect Corporation | -6.02 Million USD | 820.777% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -32159.598% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -3659.123% |
| IMV Inc. | 7.67 Million USD | -466.246% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -689.437% |
| MultiCell Technologies, Inc. | 90.04 USD | -48238460.64% |
| ONE Bio Corp. | 9.04 Million USD | -380.463% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 6017.616% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -235.501% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -3075.067% |
| Q BioMed Inc. | 4.06 Million USD | -969.801% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -42.155% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -4210.143% |
| Biomind Labs Inc. | 711.4 Thousand USD | -6005.409% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 28.263% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -2072.36% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -239.154% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11974.727% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -30967.781% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -218523.849% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1872.497% |
| GB Sciences, Inc. | 1.74 Million USD | -2385.755% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 23732.664% |
| HST Global, Inc. | 96.79 Thousand USD | -44773.08% |
| CSL Limited | 10.52 Billion USD | 99.587% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -20962.279% |
| Halberd Corporation | 144.72 Thousand USD | -29912.23% |
| Enzolytics Inc. | 981.65 Thousand USD | -4324.564% |
| Agentix Corp. | 37.63 Thousand USD | -115320.797% |
| Resverlogix Corp. | 6.45 Million USD | -573.291% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 6552.936% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 102.141% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 192.389% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -514.258% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1503.55% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 591.34% |
| AVAX Technologies, Inc. | -5.9 Million USD | 835.77% |
| Zenith Capital Corp. | 10.06 Thousand USD | -431477.901% |
| Genscript Biotech Corporation | -1.06 Billion USD | 104.092% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -21570.192% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -1720.343% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -26302.203% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 237211.038% |
| Kadimastem Ltd | -253.1 Thousand USD | 17260.67% |
| Helix BioMedix, Inc. | -2.57 Million USD | 1790.018% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -114.214% |
| BioStem Technologies, Inc. | 4.47 Million USD | -871.241% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -21481.683% |
| LadRx Corporation | -2.03 Million USD | 2232.809% |
| Cell Source, Inc. | 9.23 Million USD | -370.474% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6738.202% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6738.202% |
| NovAccess Global Inc. | 2.17 Million USD | -1893.789% |
| Affymax, Inc. | -5.59 Million USD | 876.023% |
| Itoco Inc. | 228.3 Thousand USD | -18924.55% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -31839.348% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -776.215% |
| Mobile Lads Corp. | 484.23 Thousand USD | -8869.667% |
| CytoDyn Inc. | 20.26 Million USD | -114.362% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 6713237.558% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 468727.608% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -463.639% |
| SYBLEU INC | 473.71 Thousand USD | -9068.823% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -874.507% |
| International Stem Cell Corporation | 2.59 Million USD | -1576.988% |
| Bioxytran, Inc. | 1.89 Million USD | -2187.307% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -69491.271% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1891.563% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1164.822% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -407.822% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -5521.746% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 3574.72% |
| Neutra Corp. | 52.18 Thousand USD | -83127.624% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 1845.038% |
| PureTech Health plc | -167.19 Million USD | 125.978% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 17834.823% |
| IXICO plc | -4.44 Million USD | 1077.234% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -228.573% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 20.815% |
| CSL Limited | 10.52 Billion USD | 99.587% |
| Cellectis S.A. | -43.81 Million USD | 199.122% |